Checkmate pharmaceuticals investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of checkmate pharmaceuticals, inc. - cmpi

New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of checkmate pharmaceuticals, inc. (nasdaqgm: cmpi) to regeneron pharmaceuticals, inc. (nasdaqgs: regn). under the terms of the proposed transaction, shareholders of checkmate will receive only $10.50 in cash for each share of checkmate that they own. ksf is seeking to determine whether this consideration and the
REGN Ratings Summary
REGN Quant Ranking